✦ LIBER ✦

Erlotinib treatment results in patients with advanced non-small-cell lung cancer (NSCLC)—Influence of clinical predictors

✍ Scribed by Salajka, F.; Pešek, M.; Skřičková, J.; Zatloukal, P.; Koubková, L.; Grygárková, Y.; Hrnčiarik, M.; Hejduk, K.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical surrogate markers of survival i

✍ Cedrés, Susana; Prat, Aleix; Martínez, Pablo; Pallisa, Esther; Sala, Gemma; Andr 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 341 KB

Clinical retrospective analysis of erlot

✍ Marco Platania; Francesco Agustoni; Barbara Formisano; Milena Vitali; Monika Duc 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 101 KB

Gefitinib in the treatment of elderly pa

✍ Bearz, Alessandra; Fratino, Lucia; Spazzapan, Simon; Berretta, Massimiliano; Gia 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 103 KB

Clinical efficacy of erlotinib in patien

✍ Songwen ZHOU; Shengxiang REN; Lianghua YAN; Ling ZHANG; Liang TANG; Jie ZHANG; C 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 496 KB

PCN58 A COST UTILITY ANALYSIS OF ERLOTIN

✍ PA Bradbury; R Jang; P Isogai; R Ng; N Mittmann; W Evans; FA Shepherd; NB Leighl 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Clinical effect of erlotinib as first-li

✍ Xin-Hua Xu; Jin Su; Xiang-Yang Fu; Feng Xue; Qiao Huang; Dao-Jun Li; Ming-Qian L 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 232 KB